Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells - Université de Tours Accéder directement au contenu
Article Dans Une Revue Journal of Cellular and Molecular Medicine Année : 2020

Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells

Yves Levern
Kazem Zibara

Résumé

Acriflavine (ACF) is an antiseptic with anticancer properties, blocking the growth of solid and haematopoietic tumour cells. Moreover, this compound has been also shown to overcome the resistance of cancer cells to chemotherapeutic agents. ACF has been shown to target hypoxia-inducible factors (HIFs) activity, which are key effectors of hypoxia-mediated chemoresistance. In this study, we showed that ACF inhibits the growth and survival of chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) cell lines in normoxic conditions. We further demonstrated that ACF down-regulates STAT5 expression in CML and AML cells but activates STAT3 in CML cells in a HIF-independent manner. In addition, we demonstrated that ACF suppresses the resistance of CML cells to tyrosine kinase inhibitors, such as imatinib. Our data suggest that the dual effect of ACF might be exploited to eradicate de novo or acquired resistance of myeloid leukaemia cells to chemotherapy.
Fichier principal
Vignette du fichier
2020_Hallal_J-Cell-Mol-Med_vol-24_p-10052-62.pdf (1.97 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02911576 , version 1 (22-10-2020)

Licence

Paternité

Identifiants

Citer

Rawan Hallal, Rawan Nehme, Marie Brachet‐botineau, Ali Nehme, Hassan Dakik, et al.. Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. Journal of Cellular and Molecular Medicine, 2020, 24 (17), pp.10052-10062. ⟨10.1111/jcmm.15612⟩. ⟨hal-02911576⟩
81 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More